Biohit: Sustainability of turnaround being tested
Biohit is focused on diagnostics of the gastrointestinal tract and health-promoting products. The company has shown the first signs of a turnaround after a long loss-making period. We feel a permanent turnaround of the result is likely thanks to new products, the renewed Chinese distribution agreement and effective implementation of the strategy. We believe that the development of new products and successful commercialization are key to the company's long-term success.
Biohit
Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.
Read more on company pageKey Estimate Figures30.06.2023
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 11.0 | 11.3 | 12.6 |
growth-% | 16.99 % | 3.19 % | 11.46 % |
EBIT (adj.) | 1.1 | 1.2 | 1.6 |
EBIT-% (adj.) | 10.30 % | 10.91 % | 12.44 % |
EPS (adj.) | 0.04 | 0.07 | 0.09 |
Dividend | 0.00 | 0.00 | 0.05 |
Dividend % | 2.24 % | ||
P/E (adj.) | 39.30 | 32.50 | 24.55 |
EV/EBITDA | 11.40 | 15.99 | 12.93 |